Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:JUNO
Previous Symbol
CUSIPN/A
Phone+1-206-5821600
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees553
Outstanding SharesN/A
Market Cap$0.00
OptionableOptionable
Juno Therapeutics (NASDAQ:JUNO) Frequently Asked Questions
What is Juno Therapeutics' stock symbol?
Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."
How were Juno Therapeutics' earnings last quarter?
Juno Therapeutics Inc (NASDAQ:JUNO) issued its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.07. The biopharmaceutical company earned $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. The business's quarterly revenue was up 115.4% on a year-over-year basis. During the same period last year, the firm earned ($0.57) EPS. View Juno Therapeutics' Earnings History.
What price target have analysts set for JUNO?
11 brokers have issued twelve-month target prices for Juno Therapeutics' shares. Their predictions range from $63.00 to $87.00. On average, they anticipate Juno Therapeutics' share price to reach $75.50 in the next twelve months. This suggests that the stock has a possible downside of 13.2%. View Analyst Price Targets for Juno Therapeutics.
What is the consensus analysts' recommendation for Juno Therapeutics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Juno Therapeutics in the last year. There are currently 11 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Juno Therapeutics.
Has Juno Therapeutics been receiving favorable news coverage?
News articles about JUNO stock have trended positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Juno Therapeutics earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the near term.
Who are Juno Therapeutics' key executives?
Juno Therapeutics' management team includes the folowing people:
- Howard H. Pien, Independent Chairman of the Board (Age 59)
- Hans Edgar Bishop, President, Chief Executive Officer, Director (Age 53)
- Sunil Agarwal M.D., President of Research & Development (Age 47)
- Steven D. Harr M.D., Chief Financial Officer, Head of Corporate Development (Age 46)
- Hyam I. Levitsky M.D, Executive vice president - Research, chief scientific officer (Age 54)
- Robert W. Azelby, Executive Vice President, Chief Commercial Officer (Age 49)
- Ann Lee Ph.D., Executive Vice President - Technical Operations
- Patrick Y. Yang, Executive Vice President (Age 69)
- Cynthia Elkins, Chief Information Officer
- Bernard J. Cassidy, General Counsel, Secretary (Age 62)
When did Juno Therapeutics IPO?
(JUNO) raised $153 million in an initial public offering on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Leerink Partners was co-manager.
How do I buy shares of Juno Therapeutics?
Shares of JUNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Juno Therapeutics' stock price today?
One share of JUNO stock can currently be purchased for approximately $86.96.
What is Juno Therapeutics' official website?
How can I contact Juno Therapeutics?
Juno Therapeutics' mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. The biopharmaceutical company can be reached via phone at +1-206-5821600.
MarketBeat Community Rating for Juno Therapeutics (NASDAQ JUNO)
MarketBeat's community ratings are surveys of what our community members think about Juno Therapeutics and other stocks. Vote "Outperform" if you believe JUNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JUNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
